AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15699378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day administered TID
Number of subjects: 0
Study 15699378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day administered BID
Number of subjects: 0
Study 11889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg/night)
Number of subjects: 41
Study 11889661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine (10 mg/night)
Number of subjects: 41
Study 11889661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10457249 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage and analgesia post-operatively
Number of subjects: 59
Study 10457249 — intervention group
Group type: COMPARATOR
Intervention: Analgesia post-operatively
Number of subjects: 59
Study 7842192 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 7842192 — intervention group
Group type: COMPARATOR
Intervention: No inhaled corticosteroids (Control)
Number of subjects: 0
Study 2121114 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (5 mg intravenous infusion for 60 minutes)
Number of subjects: 8
Study 2121114 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution (control)
Number of subjects: 8
Study 650201 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana extract cookies (0.3 mg/kg delta‐9‐tetrahydrocannabinol)
Number of subjects: 16
Study 650201 — intervention group
Group type: COMPARATOR
Intervention: Placebo conditions
Number of subjects: 16
Study 31566486 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 56
Study 31566486 — intervention group
Group type: COMPARATOR
Intervention: Separate laparoscopic cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 56
Study 28619269 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (ACDF, ACCF, HDF)
Number of subjects: 252
Study 28619269 — intervention group
Group type: COMPARATOR
Intervention: Laminoplasty
Number of subjects: 252
Study 28619269 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 252
Study 28619269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 252
Study 26314809 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Card (customized audio-recorded instructions)
Number of subjects: 64
Study 26314809 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 64
Study 23815538 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA
Number of subjects: 57
Study 23815538 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive controls without OSA
Number of subjects: 57
Study 21632099 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (surgery and chemotherapy) for White patients
Number of subjects: 405
Study 21632099 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment (surgery and chemotherapy) for African-American patients
Number of subjects: 405
Study 21632099 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery and chemotherapy for both racial groups
Number of subjects: 405
Study 21632099 — intervention group
Group type: COMPARATOR
Intervention: Multivariate analysis of factors associated with overall survival
Number of subjects: 405
Study 19081121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin alone (150‐200 microg/kg body weight)
Number of subjects: 182
Study 19081121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin and albendazole combination (total of 400mg)
Number of subjects: 182
Study 19081121 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 182
Study 16720865 — intervention group
Group type: EXPERIMENTAL
Intervention: Monomeric contrast agent
Number of subjects: 895
Study 16720865 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimeric contrast agent
Number of subjects: 895
Study 16720865 — intervention group
Group type: COMPARATOR
Intervention: Control group (unenhanced CT)
Number of subjects: 895
Study 16720865 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast agents
Number of subjects: 895
Study 14581415 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (arm A)
Number of subjects: 480
Study 14581415 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (arm B)
Number of subjects: 480
Study 14581415 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus gemcitabine (arm C)
Number of subjects: 480
Study 10890578 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 0.8 mg after an overnight fast (8 a.m. dosing)
Number of subjects: 24
Study 10890578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg with a high-fat breakfast (8 a.m. dosing)
Number of subjects: 24
Study 10890578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.8 mg with evening meal (6 p.m. dosing, low-fat)
Number of subjects: 24
Study 10890578 — intervention group
Group type: COMPARATOR
Intervention: Cerivastatin 0.8 mg 4 hours after dinner (10 p.m. dosing)
Number of subjects: 24
Study 8689651 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 18
Study 8689651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UF)
Number of subjects: 18
Study 1533060 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic stretching maneuver
Number of subjects: 28
Study 1533060 — intervention group
Group type: COMPARATOR
Intervention: Multimodal rehabilitation program
Number of subjects: 28
Study 3158124 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamillosan cream
Number of subjects: 161
Study 3158124 — intervention group
Group type: COMPARATOR
Intervention: 0.25% hydrocortisone
Number of subjects: 161
Study 3158124 — intervention group
Group type: COMPARATOR
Intervention: 5% bufexamac
Number of subjects: 161
Study 3158124 — intervention group
Group type: COMPARATOR
Intervention: 0.75% fluocortin butyl ester
Number of subjects: 161
Study 29692281 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology self-help book (Akhtar, 2012)
Number of subjects: 115
Study 29692281 — intervention group
Group type: COMPARATOR
Intervention: CBT self-help book
Number of subjects: 115
Study 31238925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 0
Study 31238925 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular steroid (IAS) injections
Number of subjects: 0
Study 27334135 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage
Number of subjects: 160
Study 27334135 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterization (control)
Number of subjects: 160
Study 27334135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 24778268 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT) for 12 weeks
Number of subjects: 43
Study 24778268 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Training (LIT) for 12 weeks
Number of subjects: 43
Study 24778268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HIT and LIT
Number of subjects: 43
Study 24240835 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 18
Study 24240835 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching
Number of subjects: 18
Study 24240835 — intervention group
Group type: COMPARATOR
Intervention: Comparison between serial casting and passive stretching
Number of subjects: 18
Study 21810747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mannitol (1.5 g/kg followed by 0.5 g/kg every 8 hours; n = 30)
Number of subjects: 126
Study 21810747 — intervention group
Group type: COMPARATOR
Intervention: No adjunctive therapy (n = 31)
Number of subjects: 126
Study 19417993 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Ni-Ti rocking chair arch wire
Number of subjects: 40
Study 19417993 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 16903977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0
Study 16903977 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0
Study 16903977 — intervention group
Group type: COMPARATOR
Intervention: Control (stavudine and lamivudine)
Number of subjects: 0
Study 15478147 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 109
Study 15478147 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 109
Study 11525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidine-dione derivatives
Number of subjects: 0
Study 11525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with sulphonylurea derivatives or metformin
Number of subjects: 0
Study 9145887 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 6 mg x kg(‐1) intravenously at induction of anesthesia
Number of subjects: 23
Study 9145887 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 12 mg x kg(‐1) intravenously at induction of anesthesia
Number of subjects: 23
Study 8197277 — intervention group
Group type: EXPERIMENTAL
Intervention: Good day pharmacists
Number of subjects: 389
Study 8197277 — intervention group
Group type: COMPARATOR
Intervention: Typical day pharmacists
Number of subjects: 389
Study 3129008 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg three times daily for 14 days
Number of subjects: 6
Study 29844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (30 mg twice a day continuous or 45 mg twice a day intermittent) with intravenous weekly paclitaxel (80 mg/m2)
Number of subjects: 34
Study 29844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice a day continuous)
Number of subjects: 34
Study 29844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice a day intermittent)
Number of subjects: 34
Study 29844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MAPK pathway-altered tumors
Number of subjects: 34
Study 27037553 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 62
Study 27037553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24736301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 907
Study 24736301 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 907
Study 23520213 — intervention group
Group type: EXPERIMENTAL
Intervention: MRP Support app
Number of subjects: 58
Study 23520213 — intervention group
Group type: COMPARATOR
Intervention: Static app based on MRP information
Number of subjects: 58
Study 21568691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP
Number of subjects: 185
Study 21568691 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP
Number of subjects: 185
Study 18692826 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine artery ligation and myomectomy
Number of subjects: 152
Study 18692826 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy only
Number of subjects: 152
Study 16563917 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (10 mg/day, increased to 60 mg/day as needed)
Number of subjects: 28
Study 16563917 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (1,200 ml/day) plus placebo
Number of subjects: 28
Study 12836579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 0
Study 12836579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and coping measures
Number of subjects: 0
Study 12836579 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment mediation
Number of subjects: 0
Study 12836579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive change and enhanced coping
Number of subjects: 0
Study 11308035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime major depression
Number of subjects: 136
Study 11308035 — intervention group
Group type: COMPARATOR
Intervention: No lifetime major depression
Number of subjects: 136
Study 9052581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of micronized 17 beta-estradiol (1 mg, 0.5 mg, 0.25 mg)
Number of subjects: 6
Study 9052581 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of micronized 17 beta-estradiol (1 mg, 0.5 mg)
Number of subjects: 6
Study 9052581 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration
Number of subjects: 6
Study 9052581 — intervention group
Group type: COMPARATOR
Intervention: Oral administration
Number of subjects: 6
Study 8336809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial mannitol infusion (group A)
Number of subjects: 39
Study 8336809 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial mannitol infusion (group B)
Number of subjects: 39
Study 3110799 — intervention group
Group type: EXPERIMENTAL
Intervention: T3, 100 micrograms orally
Number of subjects: 34
Study 3110799 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 34
Study 30320574 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 53
Study 30320574 — intervention group
Group type: COMPARATOR
Intervention: Music listening (ML)
Number of subjects: 53
Study 27304433 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg basimglurant MR
Number of subjects: 333
Study 27304433 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg basimglurant MR
Number of subjects: 333
Study 24856571 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cranial electrotherapy stimulation (CES)
Number of subjects: 115
Study 24856571 — intervention group
Group type: COMPARATOR
Intervention: Sham cranial electrotherapy stimulation (CES)
Number of subjects: 115
Study 23547081 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1,000 mg/m² on days 1, 8, and 15 of a 28-day cycle)
Number of subjects: 834
Study 23547081 — intervention group
Group type: COMPARATOR
Intervention: S-1 (80, 100, or 120 mg/d according to body-surface area on days 1 through 28 of a 42-day cycle)
Number of subjects: 834
Study 23547081 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus S-1 (gemcitabine 1,000 mg/m² on days 1 and 8 plus S-1 60, 80, or 100 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle)
Number of subjects: 834
Study 23547081 — intervention group
Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 834
Study 23547081 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus S-1
Number of subjects: 834
Study 23547081 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 834
Study 16002778 — intervention group
Group type: EXPERIMENTAL
Intervention: nPAP >10 cmH(2)O
Number of subjects: 10
Study 16002778 — intervention group
Group type: EXPERIMENTAL
Intervention: nPAP
Number of subjects: 10
Study 12601627 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multivitamin therapy including 1 mg of folic acid for 4 weeks
Number of subjects: 81
Study 12601627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 1 mg vitamin B(12) for an additional 4 weeks
Number of subjects: 81
Study 12601627 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin therapy (folic acid and vitamin B(12))
Number of subjects: 81
Study 12601627 — intervention group
Group type: COMPARATOR
Intervention: MTHFR genotype influence
Number of subjects: 81
Study 10921058 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 60
Study 10921058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 60
Study 10921058 — intervention group
Group type: COMPARATOR
Intervention: Manual palpation
Number of subjects: 60
Study 7832258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth diapers with front closure and all-in-one design
Number of subjects: 1722
Study 7832258 — intervention group
Group type: COMPARATOR
Intervention: Paper diapers containing absorbent gel material
Number of subjects: 1722
Study 7832258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloth diapers (second period)
Number of subjects: 1722
Study 2141299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine and naproxen
Number of subjects: 40
Study 2141299 — intervention group
Group type: COMPARATOR
Intervention: Naproxen alone
Number of subjects: 40
Study 90218 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 5 mg three times a day for 3-12 months
Number of subjects: 47
Study 90218 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 96 mg/day for 7 days
Number of subjects: 47
Study 29096938 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 1156
Study 29096938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1156
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Health news from government officials
Number of subjects: 0
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Health news from physicians
Number of subjects: 0
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: High severity condition
Number of subjects: 0
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Low severity condition
Number of subjects: 0
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mention of self-efficacy method present
Number of subjects: 0
Study 27858585 — intervention group
Group type: EXPERIMENTAL
Intervention: Mention of self-efficacy method absent
Number of subjects: 0
Study 24792763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective outcome evaluation measures (process, program, effectiveness) at Wave 3
Number of subjects: 2784
Study 24792763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective outcome evaluation measures
Number of subjects: 2784
Study 24792763 — intervention group
Group type: EXPERIMENTAL
Intervention: CPYDS scores at Wave 4
Number of subjects: 2784
Study 22743678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab (150, 300 or 600 mg)
Number of subjects: 194
Study 22743678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 20824270 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg QID)
Number of subjects: 7
Study 20824270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 19194355 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (including circumferential dissection of both the celiac axis and the superior mesenteric artery and resection of para-aortic nodes)
Number of subjects: 0
Study 19194355 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0
Study 16009860 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 3778
Study 16009860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3778
Study 16009860 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral anticoagulant agent or warfarin
Number of subjects: 3778
Study 16009860 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated or low‐molecular‐weight heparin
Number of subjects: 3778
Study 16009860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge therapy (injectable anticoagulant agent plus warfarin)
Number of subjects: 3778
Study 16009860 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 3778
Study 12450599 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 10101
Study 12450599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10101
Study 10709504 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant periodontitis patients
Number of subjects: 0
Study 10709504 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe marginal periodontitis who had responded to treatment
Number of subjects: 0
Study 10709504 — intervention group
Group type: COMPARATOR
Intervention: Healthy control individuals without marginal periodontitis
Number of subjects: 0
Study 7747700 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t‐PA)
Number of subjects: 395
Study 7747700 — intervention group
Group type: EXPERIMENTAL
Intervention: primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 395
Study 7747700 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 395
Study 2182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support during pregnancy and postnatal period
Number of subjects: 459
Study 2182977 — intervention group
Group type: COMPARATOR
Intervention: Delay of more than half an hour between birth and first suckling
Number of subjects: 459
Study 2182977 — intervention group
Group type: COMPARATOR
Intervention: Pethidine during labour
Number of subjects: 459
Study 2182977 — intervention group
Group type: COMPARATOR
Intervention: Complementary bottle feeds
Number of subjects: 459
Study 2182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 459
Study 7208079 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-painful and painful electrical stimuli
Number of subjects: 15
Study 7208079 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful electrical stimuli
Number of subjects: 15
Study 7208079 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimuli of varying intensities
Number of subjects: 15
Study 7208079 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin resistance reaction and withdrawal reflex amplitude
Number of subjects: 15
Study 7208079 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective estimation of pain
Number of subjects: 15
Study 30955909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spinal manipulation (SM)
Number of subjects: 14
Study 30955909 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 14
Study 27796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (DPP)
Number of subjects: 3535
Study 27796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (HELP PD)
Number of subjects: 3535
Study 27796775 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (HELP PD)
Number of subjects: 3535